How Kioga Bio Accelerated Clinical Research with Alethios’ End-to-End Platform

At Alethios, our mission is to make high-quality research possible for everyone—from global companies with in-house teams to early-stage innovators running their first studies.

This month, we’re thrilled to spotlight Kioga Bio, a pioneering startup developing novel postbiotics for mental resilience. Kioga is currently running a placebo-controlled interventional study of their investigational product, NeuroAlly^TM, with 60 participants—bringing big-science standards to a lean, early-stage team.

‍

Speed: Getting to market faster

Kioga’s founders needed an end-to-end platform for participant management and data collection. Existing tools left out critical elements like recruiting, onboarding, and study conclusion, leaving gaps that slowed progress. As a two-sided marketplace, Alethios draws on a pool of thousands of high-quality participants who had already expressed interest in previous studies—many of whom also own and regularly use wearable devices, making them ideal for decentralized research.

On the researcher side, Alethios automatically generates recruitment materials that meet IRB standards, reducing time spent on compliance documentation. Our team also collaborates with customers to tailor robust recruitment strategies, ensuring steady enrollment flows and a diverse participant pool.

As the Kioga team put it, “Alethios’ reach when it comes to recruitment got our trial up and running in a fraction of the time it would have taken us to do so ourselves, which will expedite our time to market in an industry where speed really matters.”

‍

Ease: A better experience for participants and teams

The NeuroAlly^TM study was intentionally designed to be straightforward, but execution required a platform that could deliver an accessible participant experience while maintaining rigor. As the co-founder and clinical research scientist, Adam Bohr, explained, “The ease and accessibility of the platform from the participant side was a massive improvement over academic-styled electronic data captures, and that is definitely reflected in our participant adherence.” That accessibility extended across all aspects of participation: in addition to at-home activities, participants completed robust onboarding, including optional Zoom appointments with on of the Kioga co-founders. These sessions, along with scheduling and task management, were handled smoothly through Alethios’ participant dashboard, which kept communication clear, reminders timely, and progress transparent.

‍

Comprehensiveness: Closing the gap

Kioga’s co-founders brought decades of experience conducting clinical trials in targeted, diseased populations, but recognized that decentralized trials in healthy people presented a different set of challenges. With a novel product to study and a need for speed, they turned to Alethios to provide the operational framework and expertise that would allow them to move forward with confidence.

As they explained, “As business owners in the dietary supplement space, we had zero experience conducting decentralized clinical trials in healthy people.” Alethios’ platform and institutional knowledge, they noted, was “invaluable in helping us bridge that gap.”

That bridge began with the Study Uploader, which generated a complete draft of their study flow—including recruitment materials, eConsent, onboarding, and ePROs—in minutes. From there, Kioga refined each piece with Alethios’ flexible editing features until the protocol matched their exact needs. Before launch, a test participant was run through the back end to confirm the flow was intuitive and seamless, ensuring the study would work just as well for participants as it did for the research team.

Bridging the Gap to Breakthroughs

For Kioga, the result is clear: less time spent on logistics and more time focused on advancing science that matters. Even while still in the middle of their 10-week study, with recruitment nearly complete, the team can view transient data as it comes in. Because every participant moves through the protocol on their own timeline, Alethios gives Kioga real-time visibility into progress without disrupting the flow of the trial.

For Alethios, it’s proof that our goal is being realized—lowering the barriers to evidence generation and giving early-stage teams the support they need to run rigorous, industry-level research with confidence.

Planning an interventional or decentralized study? Our soon-to-be-launched Alethios Startup Program may be a fit if you’re a qualified early-stage company looking to run rigorous research without building a complex tech stack from scratch. Email us to learn more before it debuts!